Business
Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease
Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n \n Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" \n or \"Kalytera\") today announced that the U.S. Patent and \n Trademark Office (\"USPTO\") issued U.S. Patent No. 9,889,100 \n B2 with claims covering the use of cannabidiol (\"CBD\") for \n the treatment of severe and refractory graft versus host disease (\"GVHD\"). \n Kalytera has exclusive worldwide rights to this issued patent through an \n Exclusive License Agreement with MOR Research Applications, Ltd. of \n Israel (“Mor”).\n \n \n GVHD is a multisystem disorder that is a life-threatening complication \n commonly occurring after bone marrow transplant procedures. GVHD occurs \n when the transplanted donor cells attack the patient’s organs, including \n the skin, gastrointestinal tract, liver, lungs and eyes. GVHD is \n associated with acute and chronic illness, infections, disability, \n reduced quality of life and death.\n \n \n In November 2017, Kalytera announced that it had received notice from \n the USPTO that the application for this patent would be allowed. The \n issuance of this patent by the USPTO is the final step in the patent \n application process, and provides patent coverage to Kalytera for the \n use of CBD in the treatment of GVHD through April 2034 under the \n Exclusive License Agreement with Mor.\n \n \n CBD is a non-psychoactive cannabis compound that possesses therapeutic \n potential across a broad range of diseases and disorders, and is being \n evaluated by Kalytera and other companies for treatment of several \n diseases and disorders other than GVHD. Kalytera’s work with CBD in the \n treatment of GVHD is expected to be the first of several programs the \n Company will undertake to investigate and commercialize this important \n compound.\n \n \n Kalytera’s ongoing Phase 2 clinical program evaluating the use of CBD in \n the prevention of GVHD is expected to be completed later this year, at \n which time Kalytera will begin preparations for the pivotal Phase 3 \n study that will be required for FDA approval. Kalytera also expects to \n initiate an additional Phase 2 clinical study in treatment of GVHD later \n this year.\n \n \n “We are delighted by the issuance of this patent for CBD in the \n treatment of GVHD,” said Robert Farrell, President and CEO of Kalytera....